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Abstract
Enteropathogenic Escherichia coli (EPEC) disease depends on the transfer of effector proteins into epithelia lining the human
small intestine. EPEC E2348/69 has at least 20 effector genes of which six are located with the effector-delivery system genes
on the Locus of Enterocyte Effacement (LEE) Pathogenicity Island. Our previous work implied that non-LEE-encoded (Nle)
effectors possess functions that inhibit epithelial anti-microbial and inflammation-inducing responses by blocking NF-kB
transcription factor activity. Indeed, screens by us and others have identified novel inhibitory mechanisms for NleC and
NleH, with key co-operative functions for NleB1 and NleE1. Here, we demonstrate that the LEE-encoded Translocated-
intimin receptor (Tir) effector has a potent and specific ability to inhibit NF-kB activation. Indeed, biochemical, imaging and
immunoprecipitation studies reveal a novel inhibitory mechanism whereby Tir interaction with cytoplasm-located TNFa
receptor-associated factor (TRAF) adaptor proteins induces their proteasomal-independent degradation. Infection studies
support this Tir-TRAF relationship but reveal that Tir, like NleC and NleH, has a non-essential contribution in EPEC’s NF-kB
inhibitory capacity linked to Tir’s activity being suppressed by undefined EPEC factors. Infections in a disease-relevant
intestinal model confirm key NF-kB inhibitory roles for the NleB1/NleE1 effectors, with other studies providing insights on
host targets. The work not only reveals a second Intimin-independent property for Tir and a novel EPEC effector-mediated
NF-kB inhibitory mechanism but also lends itself to speculations on the evolution of EPEC’s capacity to inhibit NF-kB
function.
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Introduction
The EPEC disease process depends on a protein delivery
system, encoded by the Locus of Enterocyte Effacement (LEE)
Pathogenicity Island, that transfers effector proteins directly into
the cytoplasm of infected epithelia [1–3]. This delivery apparatus
is composed of a Type Three Secretion System (T3SS) and a
filamentous extension - formed by the EPEC secreted/signalling
protein A (EspA) tipped by EspB/EspD to form a pore in the host
plasma membrane - generating a conduit for transferring effectors
into host cells [1,3]. The LEE region also encodes other factors,
including the bacterial Intimin surface protein and six effectors:
Translocated-Intimin receptor (Tir), Mitochondrial-associated
protein (Map), EspF, EspG, EspH and EspZ (with EspB also
exhibiting effector functions) [1,3]. Prototypic EPEC (E2348/69)
has at least fourteen additional non-LEE-encoded (Nle or Esp
nomenclature) effector genes distributed on six horizontally-
acquired mobile genetic elements [3,4].
The EPEC disease process is characterised by a number of
histo-pathological events including (i) initial non-intimate attach-
ment to epithelial cells, (ii) bacteria sinking into the microvillus
surface, (iii) intimate interaction with the host plasma membrane,
(iv) nucleation of actin beneath intimately-adherent bacteria and
(v) extensive loss/effacement of microvilli [1–3]. Studies with the
Caco2 small intestinal model have provided insights on these
events and revealed a plausible mechanism to explain the rapid
onset of EPEC-induced watery diarrhoea [5]. Moreover, the use of
such models have uncovered EPEC’s ability to disrupt cell-cell
interactions [5–7] subsequently verified by in vivo studies [8,9].
While disruption of cell-cell interactions is an inflammatory event,
human EPEC infections are normally associated with unexpect-
edly weak inflammation [2] thereby suggesting that the pathogen
employs inhibitory mechanisms. Indeed, studies have revealed that
EPEC inhibits Nuclear Factor kB (NF-kB) function - responsible
for inducing the expression of anti-microbial and inflammation-
related molecules - before barrier function is disrupted [10].
Host cell detection of foreign antigens (by Toll-like receptors;
TLR) and cytokines (such as TNFa and IL1b by TNFR and IL1R,
respectively) triggers a cascade of phosphorylation and ubiquitina-
tion events leading to IKK (Inhibitor of KappaB kinase) complex
activation [11–13]. The activated IKK complex, composed of two
kinases (IKKa, IKKb and a regulatory subunit (NEMO/IKKc),
phosphorylates IkB (Inhibitor of kB) to induce its proteasomal-
dependent degradation thereby releasing NF-kB for import into
the nucleus to transcribe genes [14]. NF-kB function is regulated
through many mechanisms including IkB re-synthesis, modifica-
tion of NF-kB (or accessory factors) and altering NF-kB access to
promoters [13–15]. In addition, NF-kB activity can be regulated
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includes kinases, phosphatases, ubiquitin ligases, de-ubiquitinases
and adaptor proteins [13,16–18]. TLR, IL1R and TNFR
signalling to the IKK complex depends on TNFa Receptor-
Associated Factor (TRAF) adaptor proteins and TGFb-Activating
Kinase 1 (TAK1) with pathway-specific components including
kinases such as Receptor-Interacting Protein1 (RIP1) and adaptors
such as Myeloid Differentiation primary response gene (88)
(MyD88) [13,18–20](see Fig. 1).
EPEC inhibition of NF-kB activity triggered by flagellin
(recognised by TLR5) or cytokines (including TNFa and IL1b)
in the Caco-2 small intestinal model depends on the pathogen
possessing a functional effector-delivery system [10,21]. Previous
work has argued against a need for all LEE effectors, Intimin and a
subset of Nle effectors (Orf3/EspG2, NleA, NleF and NleH) in this
EPEC NF-kB inhibitory process thereby implicating other Nle
effectors [10]. Indeed, screening programs by us and others have
revealed novel NF-kB inhibitory activities for NleC and NleH with
critical co-operative roles for NleE1 and NleB1 [22–29]. Here, we
show that the LEE-encoded Translocated-Intimin receptor has a
potent and specific Intimin-independent ability to inhibit NF-kB
activation leading to the discovery of a novel inhibitory
mechanism. Moreover, our work provides insights on the
NleE1/NleB1 subversive process and on the possible evolution
of EPEC’s capacity to inhibit NF-kB activity.
Results
EPEC inhibits NF-kB activation by targeting components
at or upstream of IKKa and IKKb
EPEC requires a functional T3SS to inhibit antigens (such as
flagellin) and cytokines (such as TNFa and IL1b) from activating
NF-kB [10,21]. To gain insight on the inhibitory mechanism, we
examined EPEC’s ability to interfere with NF-kB activity driven
by plasmid-expression of TLR/IL1R and TNFR signalling
pathway components (see Fig. 1). Thus, HeLa cells were co-
transfected with plasmids expressing luciferase under the tran-
scriptional control of NF-kB - via five repeats of the kB consensus
promoter [30] - and specific signalling pathway components [30–
32] prior to infecting with EPEC strains and quantifying luciferase
cellular activity (see Materials and Methods). As EPEC can induce
HeLa cells detachment [33], we employed the eae mutant (which
lacks the Intimin surface protein) that, like wild type EPEC,
inhibits NF-kB activity [10] but has little capacity to detach HeLa
cells (Quitard et al., unpublished). The luciferase assay revealed
basal NF-kB activity within uninfected HeLa cells as reported
[23], with no significant change following infection with the eae or
T3SS (effector-delivery defective) strains (Fig. 1A). Plasmid
expression of TNFR pathway-related kinase (IKKa, IKKb,
TAK1 and RIP1) or adaptor (TRAF2) proteins increased cellular
luciferase levels by 8 to 24 fold. Interestingly, the T3SS mutant
inhibited increases driven by plasmid-expressed RIP-1 (Fig. 1A)
supporting the presence of T3SS-independent inhibitory mecha-
nisms in the HeLa model [28,29]. By contrast, the eae mutant
infection inhibited luciferase activity driven by plasmid-expression
of all components except IKKa and IKKb (Fig. 1A). Parallel
studies on TLR/IL1R pathway components revealed another
T3SS-independent inhibitory mechanism relating to MyD88
(Fig. 1B), with the eae mutant inhibiting signalling driven by
plasmid-expressed TRAF6 and MyD88 (Fig. 1B). Western blot
analyses verified the T3SS-dependent delivery of effectors (EspF
and Tir; not shown) and plasmid-expression of examined host
proteins, with the latter revealing unexpected infection-related
increases in the cellular level of Flag-tagged TRAF proteins
(Fig. 1C). Thus, consistent with previous studies [28,29], EPEC
infection of HeLa cells inhibits signalling to NF-kB by T3SS-
independent and -dependent mechanisms. Moreover, the work
implies that T3SS-dependent inhibitory mechanism(s) relates to
effector(s) acting at or upstream of the IKKa/b complex.
The Translocated Intimin receptor inhibits TNFa-induced
NF-kB activation
To identify Nle effectors postulated to inhibit NF-kB activity
[10], putative nle effector genes [3,4] were cloned into mam-
malian expression vectors and co-transfected into HeLa cells with
the NF-kB luciferase reporter vector for screening. Indeed, this
approach identified a NF-kB inhibitory activity for NleC leading
to its definition as a zinc metalloprotease that degrades NF-kB
complexes [23] as supported by independent studies [22,24,25].
Interestingly, inclusion of an available Tir-expressing construct
[34] in the screening program indicated that this LEE effector
could prevent TNFa from activating NF-kB. To investigate this
putative NF-kB inhibitory activity in more detail, the tir gene was
sub-cloned into pEGFP-N1 to generate a Tir-eGFP fusion protein
with pEGFP-N1 serving as a negative control. Fig. 2A reveals
similar basal luciferase activity in cells transfected with pEGFP or
ptir-EGFP plasmids, with TNFa leading to a significant increase in
NF-kB reporter activity for pEGFP, but not ptir-EGFP transfected
cells. The relevance of this finding to NF-kB function was
illustrated by Western blot analysis where expression of Tir-
eGFP, unlike eGFP, inhibited TNFa from inducing the
phosphorylation-associated activation of IKKa/b kinases and
the NF-kB component, p65 (Fig. 2B). Inhibition specificity was
illustrated by unaltered total cellular levels of IKKa/b and p65
proteins (Fig. 2B). Furthermore, fluorescent microscopy exami-
nations revealed p65 within the nucleus of ,18% of eGFP or Tir-
eGFP expressing cells, with TNFa treatment increasing this to
,70% for eGFP expressing cells but only ,35% for Tir-eGFP
expressing cells (Fig. 2C). As IL8 secretion requires NF-kB
activity [35], we examined the extra-cellular levels of this
chemokine (see Materials and Methods). Consistent with the
luciferase NF-kB reporter data (Fig. 2A), pEGFP and ptir-EGFP
transfected cells released similar basal levels of IL8, with TNFa
treatment increasing IL8 secretion levels from pEGFP but not ptir-
EGFP transfected cells (Fig. 2D). Thus, expressing Tir-eGFP
within HeLa cells specifically prevents TNFa from transducing
Author Summary
Enteropathogenic Escherichia coli (EPEC) remain an impor-
tant cause of infant diarrhoea and death in developing
countries. Undoubtedly, a key pathogenic event relates to
the bacteria’s ability to inhibit the expression of anti-
microbial and inflammation-inducing molecules regulated
by the NF-kB transcription factor. This inhibitory process
was previously linked to undefined EPEC effectors blocking
NF-kB function. In this manuscript, we report that the most
extensively studied EPEC effector, Tir, possesses a potent
and specific ability to inhibit the cytokine, TNFa from
activating NF-kB. Moreover, this finding leads to the
discovery of a novel inhibitory mechanism relating to the
induced degradation of the TNFa Receptor-Associated
Factor (TRAF) adaptor protein. Additional work supports
reported NF-kB inhibitory activities for multiple non-LEE-
encoded effectors and key roles for two (identifying
possible target proteins) leading to speculations on the
evolution of EPEC’s multi-effector strategy for inhibiting
NF-kB activity.
Tir Inhibits NF-kB Activation
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the phosphorylation-associated activation of IKK components
needed to release NF-kB for nuclear import. The absence of other
EPEC factors in these experiments illustrate that this novel
property of the Translocated-Intimin receptor (Tir) effectors
occurs independently of Intimin.
Figure 1. EPEC T3SS-dependent inhibition of NF-kB activity is associated with effectors targeting pathway components upstream
of the IKK complex. HeLa cells were co-transfected with vectors encoding luciferase under the transcriptional control of NF-kB and the indicated
components of the TNFa (A) and IL1R/TLR (B) signalling pathways. Ctrl refers to control empty vector with IKK data in A and B from the same
experiment illustrating scale differences. Cells were left uninfected or incubated for 3 hours with eae (Intimin-deficient) or effector delivery-defective
(T3SS) mutants prior to (A & B) assaying cellular luciferase activity or (C) processing for Western blot analysis probing for cellular levels of actin
(loading control) and indicated signalling components. Fold increase in luciferase activity data is mean (+/- S.D.) of three independent experiments
(done in duplicate) with significance (one-way ANOVA; *p#0.05, ***p#0.005) shown relative to corresponding uninfected control.
doi:10.1371/journal.ppat.1002414.g001
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TNFa-induced IL8 secretion
To support the specific and Intimin-independent nature of the
Tirinhibitoryactivity,studiesevaluated Tir’sability toblockTNFa-
induced IL8 secretion following its delivery into HeLa cells by
Yersinia pseudotuberculosis as previously described [34]. Importantly,
the control Tir-negative Yersinia strain (which lacks most of its own
T3SS-delivered effectors) failed to inhibit TNFa-induced IL8
secretion, whereas the Tir-expressing variant inhibited this process
toa similardegreeasEPEC-deliveredeffectors(Fig.3).Westernblot
analyses verified Yersinia-delivery of Tir where it underwent partial
host kinase-mediated modification, compared to EPEC-delivered
Tir (not shown), as previously described [34]. Given that TNFa
augmentation of IL8 secretion requires NF-kB activity [35], this
work supports the premise that Tir (in the absence of other EPEC
factors, including Intimin) possesses a potent and specific ability to
prevent TNFR-induced signalling from activating NF-kB.
Tir inhibition of NF-kB activity is associated with its
targeting of the TRAF2 adaptor protein
To gain insight on how Tir inhibits TNFa-induced NF-kB
activation, HeLa cells were co-transfected with plasmids encoding (i)
the NF-kB luciferase reporter protein, (ii) TNFR signalling pathway
components and (iii) eGFP or Tir-eGFP proteins prior to assaying
cellular luciferase levels. This work revealed that Tir-eGFP, but not
eGFP, inhibited luciferase activity driven by plasmid-expression of
TRAF2 and RIP1, but not TAK1, IKKb (Fig. 4A) or IKKa (not
shown). Fluorescence microscopy studies were undertaken to deter-
mine the cellular location of over-expressed signalling components
and to assess if Tir-eGFP expression induced detectable changes.
Stainingforplasmid-expressed TirandIKKkinaseproteinsrevealed
diffuse cytoplasmic signals in contrast to cytoplasmic aggregates/
clustersfortheTRAF2(Fig.4Band Fig.S1)and MyD88(notshown)
adaptor proteins. Cytoplasmic clustering of plasmid-expressed
TRAF2 has been reported [36]. Imaging of co-transfected cells
revealed similar, distinct and partially-overlapping signals for Tir/
IKK, Tir/MyD88 and Tir/TRAF signals, respectively (Fig. 4B and
Fig. S1). Intriguingly, Tir-eGFP expression was associated with a loss
of TRAF clusters (Fig. S1B) as supported by quantification studies
(Fig. 4C). Thus, Tir may inhibit plasmid-expressed TRAF2 from
transmitting signalling to NF-kB by inducing the disaggregation
and/or degradation of activation-associated clusters.
Tir interaction with TRAF2 is associated with the
proteasomal-independent degradation of the adaptor
protein
To examine predicted Tir-TRAF interactions, GFP-Trap
beads were used to isolate eGFP and Tir-eGFP proteins from
Figure 2. Ectopically-expressed Tir is a potent inhibitor of TNFa-induced NF-kB activity. HeLa cells transfected with vectors encoding
eGFP or Tir-eGFP were treated (light grey shading or +) or not (dark grey shading or -) with TNFa prior to processing for (A) luciferase activity - these
experiments involved co-transfection with the NF-kB reporter vector, (B) Western Blot analysis probing for total and phosphorylation-associated
activated form of IKKa/b and p65 component of NF-kB, (C) microscopy-based quantification of the percentage of cells with p65 within the nucleus
(counting a minimum of 50 cells in three independent experiments), and (D) secreted levels of IL8 - a NF-kB dependent gene product. Graphical data
is mean (+/- S.D.) of three independent experiments (in duplicate for luciferase and IL8 assays) with significance (one-way ANOVA; *p#0.05, **p#0.01,
***p#0.005, ns - not significant) shown between indicated data sets.
doi:10.1371/journal.ppat.1002414.g002
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plasmid. Fig. 5A reveals eGFP and Tir-eGFP within input
cellular extracts and their isolation by the GFP-Trap beads.
While the IKKa/b proteins were present in the input pool, they
did not co-isolate with eGFP or Tir-eGFP (Fig. 5A). Probing
for Flag-tagged TRAF2 revealed a prominent monomer-sized
band with smaller amounts of a trimer-sized TRAF species in
the input pool (Fig. 5A). TRAF2 function is linked to the
formation of homo- or hetero-trimers [13,37]. Intriguingly, the
minor trimer-sized TRAF2 species preferentially isolated with
Tir-eGFP, though some monomer was co-isolated (Fig. 5A). This
work suggests that Tir interacts (either directly or indirectly) with
the activation-associated multimeric form of TRAF adaptor
proteins.
Figure 3. Yersinia-delivered Tir inhibits TNFa-induced IL8 secretion to a similar extent as EPEC-delivered effectors. HeLa cells were left
uninfected (NI) or incubated with EPEC or a Yersinia pseudotuberculosis (Yop effector-deficient) strain carrying or not a Tir-encoding plasmid (ptir)
prior to killing the bacteria, adding TNFa and quantifying IL8 secretion levels. IL8 data is mean (+/- S.D.) of three independent experiments (done in
duplicate), with significance (one-way ANOVA; ***p#0.005, ns - not significant) shown between indicated data sets.
doi:10.1371/journal.ppat.1002414.g003
Figure 4. Tir inhibition of NF-kB activation is associated with Tir targeting TRAF proteins. (A) HeLa cells were co-transfected with vectors
encoding luciferase under the transcriptional control of NF-kB and indicated components of the TNFR pathway prior to quantifying cellular luciferase
levels. Ctrl refers to control empty vector. Fold increase in luciferase activity data is mean (+/- S.D.) of three independent experiments (done in
duplicate) with significance (one-way ANOVA; *p#0.05, ***p#0.005, ns - not significant) shown relative to corresponding control. In (B) HeLa cells
were co-transfected with vectors encoding Tir-eGFP with either epitope-tagged IKKb, MyD88 or TRAF2 proteins prior to fixing cells (,24 hour post-
transfection) and probing the cellular location of the plasmid-expressed proteins (using appropriate primary and different fluorescent-conjugated
secondary antibodies). The host protein (Red) and Tir-eGFP (Green) signals collected from multiple serial slices through a field of view (,20 cells) were
obtained and plotted to display the degree of overlap. (C) Quantification of the percentage of HeLa cells containing Flag-tagged TRAF2 clusters in
eGFP and Tir-eGFP expressing cells. Data is mean (+/- S.D.) of three independent experiments examining ,50 cells per experiment (one-way ANOVA;
***p#0.005).
doi:10.1371/journal.ppat.1002414.g004
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expression may decrease the cellular levels of multimeric (and
perhaps monomeric) Flag-tagged TRAF2 protein (Fig. 5A). This
premise was supported by demonstrating that co-expression of
Tir-eGFP with Flag-tagged TRAF2 could lead to the complete loss
of TRAF2 from cell extracts, while the actin loading control
protein remained unchanged (Fig. 5B). As inflammatory signalling
is commonly regulated by targeting components for proteasomal-
dependent degradation [38], we used the proteasomal inhibitor
MG132. Whilst MG132 inhibitory activity was confirmed, as per a
parallel study [23], it failed to prevent the Tir-mediated loss of
Flag-tagged TRAF2 proteins (Fig. 5B). Interestingly, probing the
fate of endogenous TRAF2 suggested that it is not a substrate for
Tir degradation, at least in cells expressing the Flag-tagged
Figure 5. Tir interacts with TRAF2 to induce the latter’s proteasomal-independent degradation. HeLa cells were co-transfected with
vectors encoding (i) Flag-tagged TRAF2 and (ii) eGFP or Tir-eGFP proteins prior to (A) isolating Triton-X100 soluble host fractions - taking an ‘input’
reference sample - with the remaining pool used to isolate GFP proteins (ImmPpt) using GFP-Trap beads. In (B) and (C) HeLa cells were pre-treated
with the proteasome inhibitor, MG132, before and following transfection of Tir-eGFP and Flag-tagged TRAF2 plasmids, with total cellular samples
isolated 24 hr post-transfection. In (D) HeLa cells were left untransfected or transfected with pEGFP or ptir-EGFP plasmids and (24 hrs post-
transfection) incubated in the presence or absence of TNFa (30 min) prior to lysis. Samples were subjected to Western blot analysis probing with anti-
IKK, FLAG, GFP, TRAF2 and/or actin antibodies.
doi:10.1371/journal.ppat.1002414.g005
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TRAF2 bands were evident in non-transfected and ptir-EGFP
transfected cells (Fig. 5C) while the more prominent bands in
pTRAF2-transfected cells correspond to the Flag-tagged variant
(Fig. 5C versus 5B).
To investigate whether endogenous TRAF2 is a substrate for
Tir-induced degradation, its fate was examined in cells that
express Tir-eGFP, but not Flag-tagged TRAF2 proteins. Fig. 5D
reveals that Tir expression can, in fact, induce the cellular loss of
endogenous TRAF2. Interestingly, TNFa treatment of control
cells reduced the level of multimeric TRAF2 with an increase in
the monomer species (Fig. 5D) that, presumably, reflects intrinsic
host mechanism(s) for down-regulating cytokine-induced signal-
ling. By contrast, TNFa treatment of ptir-EGFP transfected cells
produced a small pool of TRAF2 protein (monomer and trimer-
sized forms; Fig. 5D) that may explain why TNFa triggered some
p65 relocation to the nucleus of Tir-eGFP expressing cells
(Fig. 2C). Ubiquitin-modified TRAF2 plays a key role in activating
RIP1 which activates TAK1 [39] to, perhaps, explain why Tir
inhibits NF-kB luciferase activity driven by plasmid-expressed
RIP1 and, to a lesser extent, TAK1 (Fig. 4A). Collectively, the
work implies that Tir inhibits TNFa-induced NF-kB activation by
interacting (directly or indirectly) with TRAF2 - a key component
of the TNFR signalling pathway - to induce its proteasomal-
independent degradation.
Tir has a non-essential contributory role in enabling EPEC
to inhibit TNFa-induced NF-kB activity
Previous work [10] suggested that the Tir and NleH effectors
are not required for EPEC to inhibit NF-kB activity, with recent
studies reporting a non-essential role not only for NleH but also
NleC [22k27]. Indeed, HeLa cells infections with a tir mutant
confirmed Tir’s non-essential role in inhibiting TNFa-induced IL8
secretion [10] but also revealed a small, but statistically significant
defect (Fig. 6A). To examine the relationship of this defect to the
absence of Tir/Intimin-mediated intimate EPEC-host cell inter-
action, assays were carried out with an eae (Intimin-deficient)
mutant. Unexpectedly, these studies indicated that Intimin
(indirectly or directly) induces NF-kB activity or suppresses
effector-mediated inhibitory mechanism(s), as the eae mutant
inhibited TNFa-induced IL8 secretion to a greater extent than
wild type EPEC (Fig. 6A). Intimin alters host cellular processes by
Tir-dependent and -independent mechanisms [40]. Infection
studies with an eaetir double mutant suggest that this Intimin
function relates to Tir-dependent and -independent mechanisms
(Fig. 6A).
Interestingly, time course infection studies support a Tir-
TRAF2 relationship as EPEC induced a dramatic loss in the
levels of activation-associated multimeric TRAF2 proteins by a
process dependent on Tir and Intimin (Fig. 6B). The Intimin-
dependent nature of this event, in contrast to that mediated by
ectopically-expressed Tir (Fig. 2), implies that EPEC has evolved
Intimin-dependent mechanisms for regulating this Tir activity.
Interestingly, other effectors appear to contribute at early time
points, with the eae mutant appearing to display an augmented
ability to reduce TRAF2 levels (Fig. 6B). Intriguingly, confocal
microscopy studies of disease-relevant polarised cells infected with
EPEC only detect Tir at the apical (surface) membrane whereas a
transient pool is evident within the cytoplasm of eae mutant-
infected cells (Fig. S2). This suggests that Intimin promotes Tir’s
rapid association with the plasma membrane, with the transient
cytoplasmic pool perhaps promoting Tir-TRAF2 interactions to
explain the eae mutant’s Tir-dependent augmented ability to
reduce the level of TRAF2 multimers and inhibit TNFa-induced
IL8 secretion.
Recent studies have described a prominent role for NleE1,
promoted by NleB1 or NleC, in the EPEC NF-kB inhibitory
process, as nleCnleE1 and nleB1nleE1 double mutants behaved like a
T3SS-defective strain, compared with partial defects for single
mutants [22,25,28,29]. However, we and others have described
T3SS-independent inhibitory mechanisms in the employed HeLa
cell models (Fig. 1) [28,29] that may obscure the contribution of
effectors (Fig. 1) [28,29]. Thus, an nleB1nleE1 double mutant was
generated and evaluated in a small intestinal model where EPEC
was confirmed to inhibit NF-kB function solely in a T3SS-
dependent manner [10] (Fig. 6C). Indeed, the nleB1nleE1 double
mutant behaved akin to the effector-delivery defective (T3SS)
strain (Fig. 6C) despite displaying no obvious defect in delivering
EspB or Tir effectors (not shown). By contrast, a nleB1nleE1tir triple
mutant displayed a small (significant) capacity to inhibit NF-kB
function - presumably due to remaining effectors. Interestingly,
while EPEC and T3SS-mutant infected cells released ,200 and
,800 ng/ml of IL8, respectively, in response to TNFa treatment
only ,400ng/ml was secreted from tir mutant infected cells
(Fig. 6C). Whilst these IL8 values support a non-essential
contributory role for Tir in the inhibitory process, the difference
between EPEC- and tir-infected cell was below the significance
threshold (p=0.075). Nevertheless, this work supports the idea
that the NleB1/NleE1 effectors play a central role in enabling
EPEC to inhibit NF-kB activity in intestinal cells, with the non-
essential novel NF-kB inhibitory activities of NleC, NleH and Tir,
presumably, playing evolutionary-advantageous roles in EPEC’s
lifecycle.
Insights on NleB and NleE targets in NF-kB signalling
Given NleE1 and NleB1’s key roles in the EPEC NF-kB
inhibitory process, with only speculations on their targets [28,29],
we investigated where the blockage occurred by co-expressing
them with signalling pathway components for NF-kB luciferase
reporter assays. Expression of NleE1 inhibited NF-kB reporter
activity driven by plasmid-expression of components from the
TNFR (TRAF2, RIP1) and IL1R/TLR (TRAF6, MyD88)
pathways (Fig. 7A) consistent with reports of it inhibiting NF-kB
activation by multiple pathways [28,29]. However, NleE1 failed to
inhibit luciferase activity driven by plasmid-expression of TAK1 or
IKK kinases (Fig. 7A) suggesting it inhibits TAK1 function to
block signalling by TNFR, IL1R and TLR pathways. NleE1 may
target TAK1 or factors needed for its activation, such as the
TAB2/3 proteins which recruit TAK1 to ubiquitin-modified RIP1
and ubiquitin-modified TRAF6 proteins for activation in the
TNFR and TLR/IL1R pathways, respectively [39]. By contrast,
NleB1 inhibited luciferase activity driven by plasmid-expression of
TRAF2 but not TRAF6 or IKKb (Fig. 7B) supporting reports of it
inhibiting signalling in TNFR but not TLR/IL1R pathways
[28,29]. Interestingly, NleB increased luciferase activity driven by
TRAF6 suggesting that it has functions that (directly or indirectly)
activate TRAF6-mediated signalling. Increases in TRAF6 signal-
ling, despite NleB inhibition of TAK1 function (Fig. 7B), suggest
that the effector may block RIP1-mediated activation of TAK1 to
inhibit signalling in TNFR, but not TLR/IL1R pathways [39].
Interestingly, our screening program revealed that the NleE1
homologue, NleE2, induced NF-kB luciferase activity as effectively
as TNFa(Fig. 7C) leading to a similar high level of p65 relocation
into the nucleus (Fig. 7D). Indeed, both these NleE2-dependent
alterations were inhibited by co-expressing Tir (Fig. 7C and 7D)
suggesting that NleE2 activates NF-kB (either directly or
indirectly) through a component at or upstream of Tir’s target
Tir Inhibits NF-kB Activation
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cells [28], our finding supports the idea that EPEC effectors have
features or functions that can activate NF-kB signalling and can be
blocked by Tir.
Discussion
In this study we describe a new property for the most-extensively
studied EPEC effector by demonstrating that the Translocated
Intimin receptor (Tir) protein has a potent and specific ability to
prevent HeLa cells from activating NF-kB in response to the
cytokineTNFa. Whilstthisdiscoveryinvolvedectopic expression of
Tir and an indirect NF-kB reporter assay, its relationship to
transcription factor function was demonstrated by several lines of
evidence. Firstly, expression of Tir-eGFP, unlike eGFP, blocked the
phosphorylation-associated activation of IKKa/b and the NF-kB
component, p65 - events required for the nuclear import and
transcriptional activity of NF-kB, respectively [13]. Importantly,
absence of these modifications was not due to cell loss as Tir-eGFP
expression had no observable impact on the total cellular level of
IKK kinases or p65. Secondly, epifluorescent microscopy studies
revealed that TNFa treatment induced some relocation of p65 into
the nucleus of Tir-eGFP expressing cells but to a dramatically less
degree than eGFP expressing cells. Indeed, as expected, these Tir-
mediated inhibitory events translated into a dramatic deficiency in
the NF-kB dependent event [35] of TNFa-augmented increases in
IL8 secretion levels. Thirdly, use of a more physiologically relevant
mechanism of introducing Tir into host cells (via the T3SS of
another pathogen, Yersinia) inhibited TNFa-induced IL8 secretion
to a similar level as control EPEC-infected cells, whereas the Tir-
negative Yersinia strain had no inhibitory capacity. Finally,
epifluorescent, biochemical and co-precipitation studies unearthed
an inhibitory mechanism relating to Tir interaction with and
subsequent cellular loss of a key component from the TNFR
signalling pathway. These data illustrate that the EPEC Tir effector
has a specific and potent ability to inhibit TNFa-induced NF-kB
activation.
The absence of additional EPEC factors in these ectopic and
Yersinia-delivery Tir experiments illustrate the Intimin-independent
nature of the NF-kB inhibitory process. Whilst over a decade of
studies has re-enforced the idea that Tir’s subversive activities
require it to interact with the EPEC surface protein, Intimin (and,
thus, Tir’s need to insert into the plasma membrane to act as a
receptor for Intimin) a recent study described an Intimin-
independent function [41]. Our discovery of a second such activity
raises the possibility that Tir possesses additional Intimin-indepen-
dent functions and the need to consider their contribution to Tir’s
critical role in the virulence of attaching and effacing pathogens that
include strains targeting humans (EPEC and enterohaemorrhagic
E. coli; EHEC), ruminants (EHEC) and various small mammals.
Our work also revealed a novel mechanism for a pathogen
effector to inhibit NF-kB activity as it demonstrated that Tir
interacts, directly or indirectly, with TRAF2 proteins (with a
preference for activation-associated multimers) inducing the
proteasomal-independent loss of this adaptor protein from host
cells. TRAF adaptor proteins play critical roles in signalling to NF-
kB by multiple pathways including the TLR, TNFR and IL1R
pathways inhibited by EPEC [10,13,19k21]. Indeed, Tir inhibited
NF-kB reporter activity driven by plasmid-expression of the
TRAF2 (Fig. 4) and TRAF6 (not shown) proteins of the TNFR
and TLR/IL1R pathways, respectively. Moreover, TRAF2 and
TRAF5 possess functionally redundant roles in TNFR-mediated
signalling to NF-kB [37] suggesting that Tir also inhibits TRAF5
activity. It is speculated that Tir can inhibit signalling through
other TRAF-dependent pathways. Six of the seven TRAF
members carry amino-terminal zinc-binding motifs involved in
their function as E3 ubiquitin ligases for activating downstream
kinases, while TRAF1 (lacks the ‘Really Interesting New Gene’
RING domain) has regulatory functions [37,42]. Studies with a
dominant-negative variant of TRAF2 [43] suggests that Tir is
unable to induce its degradation (Fig. S3) implicating a need for
the absent RING domain in the degradation process. There are
several examples of pathogens targeting TRAF proteins, including
the poxvirus MC159 protein preventing TRAF2 sequestration into
a signalosome [44] and the Yersinia YopJ effector deubiquitinating
TRAF2 to inhibit signalling to NF-kB [45]. The Yersinia strain
used in our studies has no detectable YopJ activity (linked to a
polar insertion mutation of the ypkA gene immediately upstream of
yopJ; Prof Hans Wolf-Watz personal communication). As far as we
are aware, the proteasomal-independent degradation of TRAF2
by Tir represents a novel pathogen-mediated mechanism for
inhibiting NF-kB activity. Determining if Tir induces the cellular
loss of all or a subset of TRAF members may provide insights on
the breadth of cytokine- and antigen-signalling pathways it can
inhibit and/or highlight conserved features involved in the TRAF
interaction and/or degradation processes. Studies are underway to
define the features and mechanism by which Tir induces the
proteasomal-independent degradation of TRAF adaptors.
Consistent with previous findings [10], Tir was not required for
EPEC to inhibit TNFa-induced NF-kB activation though
infection studies revealed a small, but statistically significant
inhibitory defect for a Tir-deficient strain. This defect was
unlinked to Tir’s role with Intimin in mediating intimate EPEC-
host cell interactions, as an Intimin-deficient (eae) mutant inhibited
NF-kB activity to a greater extent than EPEC. This Intimin-
related activity was associated with Tir-dependent and -indepen-
dent mechanisms thereby revealing a new property for this EPEC
surface protein. Intriguingly, strains lacking Intimin or Tir
displayed a dramatic deficiency in EPEC’s ability to decrease
cellular levels of activation-associated TRAF2 multimers suggest-
ing that, in the context of an EPEC infection, Tir requires Intimin
to reduce TRAF2 cellular levels. Interestingly, microscopy studies
identified a transient pool of Tir within the cytoplasm of epithelia
infected with the Intimin-deficient, but not wildtype EPEC strain.
While Tir has been proposed to insert into the plasma membrane
during the translocation process [46], it is clear that it can insert
Figure 6. Non-essential contribution of Tir in the EPEC NF-kB inhibitory process. In (A) HeLa cells were infected for 3 hrs with indicated
strains prior to killing the bacteria, adding TNFa (30 minutes) and quantifying of IL8 secretion levels. Data is mean (+/- S.D.) of three independent
experiments (done in duplicates) with significance (one-way ANOVA; *p#0.05, **p#0.01, ***p#0.005, ns - not significant) shown between indicated
pairs. In (B) HeLa cells were left uninfected or infected with indicated strains (using gentle centrifugation - 500 xg, 5 minutes - to synchronise
infections) and cellular samples isolated at indicated time-points for Western blot analysis probing with anti-TRAF2 antibodies. Arrow and arrowhead,
respectively, indicate monomeric and activation-associated trimeric TRAF2 forms. In (C) polarised Caco2 cells were apically-infected for 3 hours with
indicated strains prior to killing the bacteria, adding TNFa (30 minutes) to the baso-lateral surface and assaying IL8 secretion levels. Data is mean (+/-
S.D.) of three independent experiments (done in duplicates) with significance (one-way ANOVA; *p#0.05, **p#0.01, ***p#0.005, ns - not significant)
shown relative to non-infected (NI) control and between indicated pairs. Infections involved EPEC and isogenic strains lacking a functional effector-
delivery system (T3SS), Tir (tir) and/or its ligand Intimin (eae) and/or the NleB1/NleE1 (nleB1/nleE1) effectors.
doi:10.1371/journal.ppat.1002414.g006
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cytoplasmic pool has, until now, only been supported by Western
blot analyses [34,48–50]. It appears that Tir delivery into the host
cytoplasm is normally followed by its rapid (Intimin signalling-
promoted) association with the plasma membrane. The extended
presence of Tir within the cytoplasm of eae-mutant infected cells
may promote Tir-mediated loss of activation-associated TRAF2
multimers, as supported by the time course studies (Fig. 6B), to
perhaps explain the Tir-dependent increased capacity of the eae
mutant to inhibit TNFa-induced IL8 secretion.
Figure 7. NleB1 and NleE1 targets in the subversion of NF-kB activity. HeLa cells were co-transfected with vectors encoding i) luciferase
under the transcriptional control of NF-kB, ii) indicated signalling pathways components and iii) nothing (Ctrl empty plasmid), NleE1 (in A) or eGFP-
NleB1 (in B) prior to assaying cellular luciferase activity. Relative luciferase activity, as percentage of control, is given as mean (+/- S.D.) of three
independent experiments (done in duplicate; A) and one experiment (done in duplicate; B). In C and D, HeLa cells were transfected with Control
(empty plasmid), NleE2 and/or Tir-eGFP encoding vectors prior to treating (light grey box) or not (dark grey box) with TNFa and processing for (C)
luciferase activity - these experiments involved cotransfection with the NF-kB reporter vector or (D) microscopy-based quantification of the
percentage of cells with p65 in the nucleus (counting a minimum of 50 cells). Data shown is mean (+/- S.D.) of three independent experiments with
luciferase assays done in duplicate.
doi:10.1371/journal.ppat.1002414.g007
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process, like that of NleC and NleH [22–27], could be due to
functional redundancy with other effectors, this is not the case as
illustrated by studies with an nleB1nleE1 double mutant. Thus,
despite displaying no defect in delivering Tir into host cells, the
double mutant had no significant ability to inhibit TNFa-induced
IL8 secretion in HeLa or small intestinal models. This finding
supports the reported key role for the NleE1/NleB1 effectors in
blocking NF-kB function [25,28,29] and implies that the described
novel NF-kB inhibitory activities of Tir, NleH and NleC effectors
[22–27] (this study) are minor or transient during EPEC infections.
As Yersinia-delivered and ectopically-expressed Tir proteins are
potent inhibitors of TNFa-induced NF-kB activity, unlike EPEC-
delivered Tir, this implies that EPEC possesses factors that
suppress Tir’s inhibitory function. Interestingly, ectopically-
expressed Tir decreases TRAF2 cellular levels in an Intimin-
independent manner (Fig. 5) while decreases mediated by EPEC-
delivered Tir depend on Intimin (Fig. 6B). Ectopically-expressed
(and Yersinia-delivered) Tir differs from the EPEC-delivered Tir by
i) being mainly cytoplasmic ii) only undergoing partial host kinase-
mediated modification and iii) failing to interact with Intimin [34]
(Fig. S3). Thus, EPEC suppression of Tir’s ability to decrease
TRAF2 cellular levels (and presumably its ability to inhibit NF-kB
activity) is linked to undefined EPEC factors enabling Tir to insert
into the plasma membrane to interact with Intimin. Further
studies are required to define the putative EPEC factors and
mechanisms involved in this regulatory process.
Our screening program revealed NF-kB inhibitory activities for
NleC [23] and Tir (this study), a NF-kB activatory function of
NleE2 (this study) and confirmed inhibitory activities [22–29] for
NleH (not shown), NleE1 (this study) and NleB1 (this study)
effectors. By contrast, no significant NF-kB modulatory activity
was evident from screening other LEE or non-LEE effectors,
though it is possible that the findings included false negatives due
to effector expression problems or expressing effector-fusion
proteins. Indeed, our work supports the premise [22–27] that
NleC and NleH inhibit NF-kB function by targeting components
downstream of the IKK complex [23] (not shown), with the
inhibitory activities of NleE1, NleB1 and Tir linked, respectively,
to blocking the function of the TAK1, RIP1 and TRAF
components upstream of IKK. Interestingly, while NleB1
inhibited signalling by TNFR pathway components, it promoted
that mediated by the TLR/ILIR pathway protein, TRAF6 (but
not downstream RIP1) suggesting that it has properties that induce
TRAF6-mediated NF-kB activation. Indeed, the idea that EPEC
effector features or properties can activate NF-kB is supported by
the finding that ectopically-expressed NleE2 was as effective as
TNFa at inducing p65 nuclear relocation. Interestingly, this
NleE2-mediated event was blocked by co-expression of Tir
suggesting that its activatory property, as per NleB1, is transmitted
through TRAF proteins - a defined target of Tir to inhibiting
signalling to NF-kB.
Our findings on LEE and Nle effectors, in light of published
work, lend themselves to speculations on the evolution of EPEC’s
capacity to inhibit NF-kB. Genome sequencing projects suggest
that pathogenic E. coli evolved from commensal E. coli through the
horizontal-acquisition of new functions encoded on mobile genetic
elements. Thus, enterotoxigenic E. coli (ETEC) virulence is linked
to strains acquiring functional enterotoxins and an enterocyte-
binding pilus [51], whilst that of EPEC is linked to the acquisition
of the effector-encoding mobile genetic elements [4,52]. As Nle
effector genes are generally missing from non-pathogenic E. coli
strains and require the LEE T3SS for delivery into host cells, it is
reasonable to assume that the progenitor EPEC strain possessed
the LEE, but not Nle-encoding genetic elements. EPEC factors
(including flagella) and LEE subversive functions (eg disrupting
cell-cell interactions) can activate NF-kB to induce the expression
of anti-microbial and inflammatory molecules that inhibit EPEC’s
virulence-critical ability to colonise epithelia [10,21]. Thus, the
LEE region presumably encoded factor(s) to inhibit this event, with
our screening program defining Tir as the only LEE effector with
significant NF-kB inhibitory activity. Indeed, our definition of Tir-
TRAF interactions within the cytoplasm to inhibit NF-kB activity
may explain why Tir transits through this host compartment prior
to inserting into the host membrane. It is possible that Tir’s
inability to completely block signalling-induced relocation of NF-
kB into the nucleus (Fig. 2C) provided a selective advantage to
strains acquiring mobile genetic elements expressing effectors that
promote the inhibitory process (eg NleC degradation of nuclear
NF-kB complexes). Undoubtedly, the key point in the evolutionary
process relates to the acquisition of the NleB1/NleE1-encoding
mobile genetic element (Integrative element 6; IE6) given their
critical roles in blocking NF-kB activation in HeLa cells [25,28,29]
and disease-relevant small intestinal models. This premise is
supported by the nleB1nleE1 genes being among the subset of nle
genes found in all sequenced LEE-encoding pathogens [52] and
their presence at the 39 end of the LEE region in some
enterohemorrhagic E. coli strains [53]. It is possible that this
LEE/IE6 hybrid represents a minimal genetic unit required to
provide strains with EPEC-like enteric pathogenic properties.
Materials and Methods
Bacterial strains, growth condition and cell culture
These studies used nalidixic acid resistant EPEC strains,
specifically wild-type EPEC (E2348/69), eae (Intimin-deficient)
and espA (T3SS-deficient) isogenic strains [54,55]. The nleB1nleE1
double mutant was generated using described standard allelic
exchange procedures [56,57] to remove (confirmed by PCR
analyses) the entire gene sequence (and inter-gene region) of the
adjacent nleB1 and nleE1 genes. The nleB1nleE1tir triple mutant
was generated using an available tir-deletion suicide vector as
described [57]. Strains were grown in Luria-Bertani (LB) broth
containing nalidixic acid (25 ug/ml final conc.) from single
colonies, without shaking, at 37uC in a 5% CO2 incubator
overnight. The Yersinia strains and their usage was as previously
described [34]. Hela cells (ATCC CCL2) were grown at 37uC with
5% CO2 in Dulbecco’s Minimal Eagles Medium (DMEM)
supplemented with 10% heat-inactivated foetal calf serum and
2 mM L-glutamine. Caco2 parental or TC7 subclone cells were
seeded at confluence onto Transwells (Corning) and polarised over
12–15 days as previously described [5,6].
Plasmids
Prof Luke O’Neill (Trinity College, Dublin) kindly provided
plasmids relating to the NF-kB luciferase-reporter construct and
expression of IKKa, IKKb, TRAF2, TRAF6, and MyD88 [30]
with those for RIP1 [31] and TAK1 [32] kindly provided by Prof’s
Ju ¨rg Tschopp (University of Lausanne, Switzerland) and Martin
Dorf (Harvard, USA), respectively. Tir-eGFP, eGFP-NleB1,
NleE1 and NleE2 proteins were expressed from pEGFP-N1
(Clontech), pEGFP-C1 (Clontech), pIRES (Clontech) and
pcDNA3 (Invitrogen) vectors, respectively.
Luciferase reporter assay
Hela cells (,2610
5) seeded in 24-well plates were transfected
the following day using JetPrime reagent (PEQLAB Ltd, UK) with
a total amount of 250 ng DNA, comprising 100 ng of the NF-kB
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reniformis luciferase plasmid plus 110 ng of empty, or effector
gene-containing plasmid. Levels of firefly luciferase expression
were normalised against Renilla luciferase activity as a control for
transfection efficiency (expressed as fold increase in luciferase
activity over unstimulated control cells). When transfection
efficiency was routinely found to be ,65–80%, the Renilla
luciferase plasmid was replaced with empty plasmid. High
transfection efficiencies for pEGFP and/or pEGFP-tir experiments
were routinely verified by visualising the eGFP signal. Twenty four
hours post transfection, cells were incubated with or without
TNFa (10 ng/ml) for 30 minutes, lysed in 100 ml of passive lysis
buffer (Promega Ltd, Southampton, UK) for 15 minutes at room
temperature with cell extracts taken for assessment of firefly
luciferase activity following standard protocols and a FLUOstar
Optima 413-3266 plate reader (BMG Labtech, Germany).
Infection protocols
LB grown EPEC cultures were first diluted (1:10) in DMEM
and incubated for 3 hours at 37uC in a 5% CO2 incubator. The
typical optical density (OD600) was between 0.2–0.3 with infections
carried out at a multiplicity of infection, MOI, of ,100:1. The
HeLa cell medium was replaced with DMEM at least 2 hours
prior to infection (routinely 3 hours unless stated otherwise), with
studies on transfected cells normally 24 hours post-transfection.
Yersinia YIII MEKA strains were grown in modified brain-heart
medium supplemented with 20 mM MgCl2 and 5 mM EGTA at
26uC without shaking, and used for infections as previously
described [34]. When appropriate, cells were incubated with
bactericidal levels of gentamycin (100 mg/ml final conc.) for
1 hour prior to adding TNFa (10 ng/ml) for between 30 minutes
(the routine) and up to 2 hours. EPEC infections did not induce
significant cell detachment under the employed experimental
conditions.
Immunoblotting
HeLa cells were washed with cold Phosphate Buffered Saline
pH 7.4 (PBS) and lysed with 1% Triton X-100 in the presence of
protease inhibitors (1/1000 dilution, Sigma cocktail), sodium
fluoride, sodium orthovanadate and PMSF (1.2, 1.2 and 1 mM
final concentration, respectively). When appropriate centrifugation
(13000 x g 5 minutes) was used to separate insoluble (contains host
nuclei and cytoskeleton as well as adherent bacteria) and soluble
(contains host cytoplasmic and membrane proteins as well as
T3SS-delivered proteins). Samples were resolved on 10% SDS
PAGE, transferred onto nitrocellulose, blocked in 5% Blotto milk
powder/PBS/0.02% Tween and probed with antibodies against
IKKa/b (Santa Cruz), phospho IKKa/b (Cell Signaling), NF-kB
p65 (Santa Cruz), phospho p65 (Ser536), TRAF2 (Cell Signaling),
actin (Sigma), FLAG tag (Sigma), Myc tag (generous gift; Prof D.
Mann, Newcastle University) or GFP (Zymed). Absence of
reducing agents allowed the detection of TRAF2 multimeric
bands. Primary antibodies were incubated overnight in a 5%
bovine serum albumin (BSA)/PBS solution, washed extensively.
Bound antibodies were detected using horseradish peroxidase-
conjugated secondary antibodies and Super Signal West Pico
chemiluminescent substrate (Pierce) with Hyperfilm ECL (Amer-
sham Biosciences) following the manufacturer’s recommendations.
IL8 secretion assay
Supernatants (0.5 ml) were taken from above the HeLa cells
and assayed for the level of IL8 using an ELISA kit (DB
Biosciences) following the manufacturer’s recommendations.
Immunoprecipitation studies
Immunoprecipitation of Tir-eGFP was performed using GFP-
Trap A beads (Chromotek) according to the manufacturer’s
instructions. Briefly, 24 hours post-transfection, Hela cells were
lysed in RIPA buffer, centrifuged and the supernatant incubated
with GFP-Trap beads for 30 minutes at 4uC. Following
centrifugation, the unbound material was harvested and the beads
washed before being resuspended in sample SDS buffer for
Western blot analyses.
Immuno-fluorescence microscopy
Following experimentation, Hela cells seeded on glass coverslips
were washed three times with PBS prior to fixing (2.5%
Paraformaldhyde - Sigma - in PBS) for 30 minutes and
permeabilisation of host membranes in Triton-X100/BSA (0.1%
and 2.5% final conc, respectively)/ PBS solution for 30 minutes.
Cells were then incubated overnight in the fridge with an
appropriate primary antibody in 2.5% BSA/PBS solution,
followed by multiple PBS washes and incubation with Alexa 488
or Alexa 555-conjugated secondary antibodies in a 2.5% BSA/
PBS solution (1 hour; room temperature). Washed cells were
mounted in DAPI-Vectashield (Vector Laboratories) and exam-
ined on a Zeiss Axioskop Epifluorescent or a Leica TCS SP2UV
confocal microscopy. Nuclear p65 and TRAF clusters were
counted in a semi-blind fashion i.e. slides were assessed without
considering the slide order or orientation with obtained data
mapped to labelling. For co-localisation studies, cells were
visualised using the confocal microscope using an x63 objective
lens with serial optical slices taken along the z-axis of cells within a
field of view (,20 cells), with signals analysed by Leica software
and plotted to illustrate the degree of overlap.
Supporting Information
Figure S1 Near-complete and partial colocalisation of
Tir with IKKb and TRAF2 proteins, respectively, with
Tir expression linked to disruption of TRAF2 clusters.
HeLa cells were co-transfected with vectors encoding Tir, IKKb
and/or TRAF2 (see Materials and Methods) prior to fixing (,24
hour post-transfection) and examining the cellular location of Tir
(GFP signal; Green), TRAF2 or IKK (appropriate primary
antibody and fluorescent-conjugated secondary antibodies; Red)
and nuclear DNA (via DAPI; blue). Viewing of signals (via a Leica
SP2 confocal microscope) reveals in A) diffuse patterns for Tir
(Green) and IKKb (Red) with very high levels of co-localisation
(yellow/orange colour in overlap), B) the presence of distinct
cytoplasmic-located TRAF2 clusters (Red) with C) co-localisation
of Tir with TRAF2 clusters (yellow/orange colour in overlap)
linked to their disaggregation.
(TIF)
Figure S2 Absence of Intimin leads to a detectable pool
of Tir within the host cytoplasm of infected polarised
cells. Cells of the Caco-2 subclone, TC7, were seeded at
confluence onto Transwells (Corning) for polarisation over 12–
15 days. EPEC strains (pre-activated in DMEM at 37uC) were
infected at an MOI of 1:200 using gentle centrifugation (500 xg, 5
minutes) to initiate and synchronise EPEC-apical surface interac-
tions. At indicated time points, the cells were washed and
processed for microscopy as described [6]. Cells infected with
wildtype EPEC (A) or the Intimin-deficient (eae) mutant (B) were
stained to detect Tir (Green; anti-Tir antibodies), filamentous actin
(Red; TRITC-phalloidin) and DNA (DAPI) prior to viewing on a
Leica SP2 confocal microscope. Cells infected with a tir-deficient
mutant were used as the negative control to ensure background
Tir Inhibits NF-kB Activation
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deficient) mutant infected cells. Images show the xz-axis of the
monolayer with images representative of those obtained from two
independent experiments.
(TIF)
Figure S3 Tir does not induce the cellular loss of a
dominant-negative variant of TRAF2. Hela cells were
transfected with vectors encoding TRAF2 or a dominant-negative
variant [43] along with vectors encoding eGFP or eGFP-Tir prior
to isolating total cellular extracts (24 hr post-transfection) and
probing for TRAF2, Tir and actin (latter as a loading control).
Arrow indicates a host-kinase modified Tir form, as reported [34].
(TIF)
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